A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

This trial is open to adults aged 18 and over who have been diagnosed with cancer that has spread to other areas of the body. Specifically, the study is looking for people with advanced bowel (colorectal) cancer, non-small cell lung cancer, kidney (renal) cancer, or sarcoma (cancer of the soft tissues or bones).

Because the study uses targeted radiotherapy, participants usually need to have tumours in areas that doctors can safely treat with SABR. You will also need to be well enough in your day-to-day life to undergo regular hospital visits, scans, and treatments.

You may not be able to take part if you have certain other medical conditions, severe auto-immune diseases, or if you have recently had treatments that might interfere with how the trial medicine works. The trial doctor will review your medical history and scans to check if this study is suitable for you.

If you decide to take part, you will first have screening tests, including blood tests and scans, to confirm the trial is right for you. You will then receive the immunotherapy drug atezolizumab as an intravenous drip, typically given in hospital every few weeks. Alongside this, you will have sessions of SABR radiotherapy, which are quick, painless, and delivered across a small number of outpatient appointments.

Throughout the study, you will have regular hospital check-ups and imaging scans (such as CT or MRI scans) to track how your tumours are responding. Doctors will also check your blood and ask how you are feeling to record any side effects. Your active treatment and monitoring will last for at least a year, followed by long-term check-ins. Taking part does not require overnight hospital stays unless extra monitoring is needed.